Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 7Completed 7Active not recruiting 4Terminated 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 58Breast Neoplasms 54Lymphoma 52Multiple Myeloma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Leukemia 48Lymphoma, Non-Hodgkin 46Melanoma 43Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 40Myelodysplastic Syndromes 39Lymphoma, Follicular 29Burkitt Lymphoma 25Hodgkin Disease 24Neoplasm Metastasis 22Recurrence 21Neoplasms 21Lymphoma, Mantle-Cell 20Lymphoma, B-Cell, Marginal Zone 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Primary Myelofibrosis 14Neoplasms, Plasma Cell 14Myeloproliferative Disorders 14Lymphoma, B-Cell 14Hematologic Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Carcinoma, Renal Cell 13Triple Negative Breast Neoplasms 12

Interventions

blinatumomab 3Cytarabine 2Cyclophosphamide 2Azacitidine 2venetoclax 1sabatolimab 1ruxolitinib 1pulrodemstat besilate 1pembrolizumab 1peginterferon alfa-2a 1nilotinib 1fludarabine 1daratumumab 1Zoledronic Acid 1Vitamin D 1Methotrexate 1Imatinib Mesylate 1GNKG168 1Dasatinib 1Clofarabine 1Celecoxib 1Calcium 1CD3 Complex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasm, Residual × Cyclophosphamide × Clear all
NCT05601830 2024-11-06

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Terminated
1 enrolled
Tumor-Agnostic

Neoplasm, Residual

NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡